Clinical Trials Browser

Phase 2 × Multiple Myeloma × Bendamustine Hydrochloride × Clear all

NCT02224729 2025-04-30

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

24 enrolled 13 charts

Multiple Myeloma

NCT03187223 2025-01-30

BEB-2

Phase 2 Completed

120 enrolled 11 charts

Multiple Myeloma

NCT02424851 2022-01-27

OPTIMAL

Phase 2 Completed

31 enrolled 13 charts

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01045681 2020-12-07

BVD

Phase 2 Completed

Multiple Myeloma

NCT02237261 2020-10-19

BPV

Phase 2 Completed

Multiple Myeloma

NCT01438177 2020-02-24

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

Phase 2 Terminated

11 enrolled 9 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01526694 2018-07-03

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT01315873 2018-02-07

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Phase 2 Terminated

24 enrolled 3 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01332617 2017-12-29

Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01110135 2017-05-24

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Phase 2 Completed

43 enrolled 5 charts

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01056276 2017-05-03

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Phase 2 Completed

59 enrolled 9 charts

Multiple Myeloma

NCT01701076 2016-08-24

BRd

Phase 2 Completed

Multiple Myeloma

NCT01376401 2016-05-17

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Phase 2 Completed

Multiple Myeloma

NCT01168804 2013-11-25

BBD

Phase 2 Completed

Multiple Myeloma